‘Drastic’ Japan Price Reforms Hitting R&D Incentives, Plans - EFPIA

European research-based pharma group proposes reconsideration of Japan’s revised pricing system, warning it is already affecting corporate R&D decisions and will stifle industry investment, innovation and patient access to new therapies if incentives are not improved.

Tokyo skyline and Mountain Fuji in Japan
EFPIA Proposes Changes To Japan Pricing Scheme • Source: Shutterstock

The European research-based pharma industry federation EFPIA is warning that the “drastic” new criteria for the price-setting of original drugs adopted in Japan in April are unduly focused on short-term government cost savings, and are already prompting some its local members to revise their R&D strategies given increased business uncertainty.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

More from Focus On Asia